Overactive Bladder Treatment Market, By Product Type (Anticholinergics, Mirabegron, Botox, and Others), By Application (Idiopathic Bladder Overactivity, and Neurogenic Bladder Overactivity), Industry Trends, Estimation & Forecast, 2014-2026

Check Today's Best Price

$3500 Buy Now
The global Overactive Bladder Treatment market is valued at XX million US$ in 2018 is expected to reach 4,712.3 million US$ by the end of 2026, growing at a CAGR of 2.9% during 2019-2026.
  • Market Overview

    The global Overactive Bladder Treatment market is valued at XX million US$ in 2018 is expected to reach 4,712.3 million US$ by the end of 2026, growing at a CAGR of 2.9% during 2019-2026.

    Overactive bladder (OAB) is a condition that causes an urge to urinate. OAB can be managed through behavioral techniques and medications. Overactive bladder (OAB) can be caused by Parkinson’s disease, diabetes, multiple sclerosis, or kidney disease. Overactive bladder is a disorder that causes symptoms such as sudden, uncontrollable urge to urinate, leaks, and frequent visit to the bathroom during both the day and the night. The medications for the treatment for overactive bladder, and it also reduce episodes of urge incontinence. The drugs include Tolterodine (Detrol, Detrol LA), Oxybutynin (Ditropan XL), Oxybutynin as a skin patch (Oxytrol), Oxybutynin gel (Gelnique, Gelnique 3%), Trospium (Sanctura), Solifenacin (Vesicare), Darifenacin (Enablex), Mirabegron (Myrbetriq), and Fesoterodine (Toviaz). OnabotulinumtoxinA, also called Botox. It is a protein from the bacteria, used in small doses directly injected into bladder tissues, this protein partially paralyzes muscles.

    Overactive Bladder Treatment Market value-2014-2026

    Market Driver

    The increasing prevalence of overactive bladder and Urinary Incontinence is boosting the global overactive bladder treatment market. For instance, According to the Urology Care Foundation, in 2017, at least 33 million people in the United States have overactive bladder.

    According to the National Association for Incontinence, in 2016, Urinary Incontinence affects 200 million people worldwide. Urinary Incontinence is twice as common in women as in men. Twenty-five million adult Americans suffering from some form of urinary incontinence, of which 75-80% of those are women. In 2016, Stress urinary incontinence, the most prevalent form of incontinence among women, affected an estimated 15 million adult women in the U.S in 2016. In the U.S in 2016, around 17% of women and 16% men over 18 years old have overactive bladder (OAB), and an estimated 12.2 million adults have urge incontinence. In 2016, the ages between 18 and 44, approximately 24% of women experienced incontinence, and for women over age 60, approximately 23% deal with incontinence in the U.S.

    Market Restraint

    The side effects of overactive bladder medication might hamper the global overactive bladder treatment market. All the medication has a different side effect such as Antimuscarinic medication side effects include dry mouth, constipation, dry or itchy eyes, blurred vision, indigestion, urinary tract infection, urinary retention, and drowsiness. Mirabegron (Myrbetriq), most commonly reported side effects are high blood pressure, urinary tract infection, and headaches.

    Segment Analysis

    Based on product type, the global Overactive Bladder Treatment market is broadly segmented as Anticholinergics, Mirabegron, Botox, and Others. In 2018 Anticholinergics is the dominant segment, and it accounts for approximately 80% of the market.

    Anticholinergic drugs block the action of acetylcholine, that sends signals to the brain, which trigger abnormal bladder contractions associated with overactive bladder. Anticholinergic are usually given as a pill or tablet. Oxybutynin is also available as a cream or skin patch that delivers medication for overactive bladder. Anticholinergic medications include Oxybutynin (Ditropan XL, Oxytrol), Tolterodine (Detrol), Darifenacin (Enablex), Solifenacin (Vesicare), Trospium, and Fesoterodine (Toviaz)

    The increasing regulatory approval for Anticholinergics is boosting the global Overactive Bladder Treatment market. For instance, on May 21, 2019, Alembic Pharmaceuticals and Glenmark Pharmaceuticals have received FDA approval for generic solifenacin succinate tablets, 5 mg and 10 mg, a therapeutic equivalent to Astellas’ Vesicare tablets, 5 mg, and 10 mg. Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urgency, urge urinary incontinence, and urinary frequency. The regulatory approval for manufacturing Anticholinergics is boosting the global Overactive Bladder Treatment market. For instance, on July 19, 2018, Cipla has received USFDA approval to manufacture Solifenacin Succinate (gVesicare). Solifenacin Succinate is an antispasmodic, and it is used to relieve symptoms associated with an overactive bladder. The drug is marked by Astellas Pharma as Vesicare.

    Overactive Bladder Treatment Market by type - 2018

    Mirabegron has shown significant growth in 2018, and it is expected to increase in the upcoming years, due to the increasing regulatory approvals. For instance, on June 27, 2019, Lupin, has received tentative approval from the US health regulator for the generic version of Mirabegron Extended-Release (ER) tablets of Astellas Pharma Global Development Inc. The approval is for the generic version of Mirabegron ER tablets of strengths 25 mg and 50 mg, Lupin said in a statement. The medicine is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

    Regional Analysis

    The global Overactive Bladder Treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

    North America is dominating the global Overactive Bladder Treatment market, due to the growing incidence of overactive bladder in the U.S. For instance, Overactive Bladder, in 2017, around 16% of the adult American population has overactive bladder (OAB). About 40% of American women and 30% of American men have experience OAB symptoms in 2017.

    The regulatory approval for the combination of two product type, Anticholinergics, and Mirabegron for the treatment of Overactive Bladder is boosting the North America Overactive Bladder Treatment market. For instance, in May 23, 2018, Astellas Pharma Inc., have received the U.S. Food and Drug Administration (FDA) approval a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. In the United States, mirabegron and solifenacin succinate are marketed as Myrbetriq and VESIcare.

    The North America Overactive Bladder Treatment market size was XX million USD in 2018, and it will be 2,862.1 million USD in 2026, with a CAGR 2.8% from 2019 to 2026.

    Competitive Analysis

    The major players include Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical Industries Limited, Allergan, PLC, Mylan N.V, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc., Sanofi, Aurobindo Pharma Limited, and Johnson & Johnson.

    The introduction of solifenacin succinate medication is boosting the global Overactive Bladder Treatment market. For instance, April 22, 2019, Teva Pharmaceutical Industries Ltd., have introduced a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S. Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

    The distribution of overactive bladder medication is boosting the global Overactive Bladder Treatment market. For instance, on May 9, 2017, Duchesnay, have started the distribution of Mictoryl and Mictoryl Pediatric (propiverine hydrochloride) in Canada for the symptomatic treatment of urinary incontinence and increased urinary frequency and urgency in patients with overactive bladder (OAB).

    Global Overactive Bladder Treatment Market

    • Consumption by Regions
      • North America
      • Europe
      • China
      • Japan
      • Rest of the World
    • Segment by Type
      • Anticholinergics
      • Mirabegron
      • Botox
      • Others
    • Segment by Application
      • Idiopathic Bladder Overactivity
      • Neurogenic Bladder Overactivity
    keyboard_arrow_up
  • Table of Content

    1 Overactive Bladder Treatment Market Overview
    1.1 Product Overview and Scope of Overactive Bladder Treatment
    1.2 Classification of Overactive Bladder Treatment by Type
    1.2.1 Global Overactive Bladder Treatment Market Revenue Comparison by Type (2019-2026)
    1.2.2 Global Overactive Bladder Treatment Revenue Market Share by Type in 2018
    1.2.3 Anticholinergics
    1.2.4 Mirabegron
    1.2.5 Botox
    1.2.6 Others
    1.3 Global Overactive Bladder Treatment Market by Application
    1.3.1 Global Overactive Bladder Treatment Market Size and Market Share Comparison by Applications (2019-2026)
    1.3.2 Idiopathic Bladder Overactivity
    1.3.3 Neurogenic Bladder Overactivity
    1.4 Global Overactive Bladder Treatment Market by Regions
    1.4.1 Global Overactive Bladder Treatment Market Size (Million USD) Comparison by Regions (2019-2026)
    1.4.2 North America (USA, Canada, and Mexico) Overactive Bladder Treatment Status and Prospect (2014-2026)
    1.4.3 Europe (Germany, France, UK, Russia, and Italy) Overactive Bladder Treatment Status and Prospect (2014-2026)
    1.4.4 Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) Overactive Bladder Treatment Status and Prospect (2014-2026)
    1.4.5 South America (Brazil, Argentina, Colombia) Overactive Bladder Treatment Status and Prospect (2014-2026)
    1.4.6 The Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa) Overactive Bladder Treatment Status and Prospect (2014-2026)
    1.5 Global Market Size of Overactive Bladder Treatment (2014-2026)

    2 Company Profiles
    2.1 Astellas Pharma Inc.
    2.1.1 Company Basic Information and Its Competitors
    2.1.2 Astellas Pharma Inc. Product Category
    2.1.2.1 MYRBETRIQ (mirabegron)
    2.1.3 Astellas Pharma Inc. Overactive Bladder Treatment Revenue (2017-2018)
    2.1.4 Astellas Pharma Inc. Recent Developments
    2.1.5 Main Business/Business Overview
    2.2 Pfizer, Inc.
    2.2.1 Company Basic Information and Its Competitors
    2.2.2 Pfizer, Inc. Product Category
    2.2.2.1 TOVIAZ
    2.2.3 Pfizer, Inc. Overactive Bladder Treatment Revenue (2017-2018)
    2.2.4 Main Business/Business Overview
    2.3 Teva Pharmaceutical Industries Limited
    2.3.1 Company Basic Information and Its Competitors
    2.3.2 Teva Pharmaceutical Industries Limited Product Category
    2.3.2.1 VESIcare (solifenacin succinate)
    2.3.3 Teva Pharmaceutical Industries Limited Overactive Bladder Treatment Revenue (2017-2018)
    2.3.4 Teva Pharmaceutical Industries Limited Recent Developments
    2.3.5 Main Business/Business Overview
    2.4 Allergan plc
    2.4.1 Company Basic Information and Its Competitors
    2.4.2 Allergan plc Product Category
    2.4.2.1 BOTOX (onabotulinumtoxinA)
    2.4.3 Allergan plc Overactive Bladder Treatment Revenue (2017-2018)
    2.4.4 Allergan plc Recent Developments
    2.4.5 Main Business/Business Overview
    2.5 Mylan N.V.
    2.5.1 Company Basic Information and Its Competitors
    2.5.2 Mylan N.V. Product Category
    2.5.2.1 TOLTERODINE TARTRATE
    2.5.3 Mylan N.V. Overactive Bladder Treatment Revenue (2017-2018)
    2.5.4 Main Business/Business Overview
    2.6 Endo International Plc
    2.6.1 Company Basic Information and Its Competitors
    2.6.2 Endo International Plc Product Category
    2.6.2.1 Oxybutynin Chloride 10% Gel
    2.6.3 Endo International Plc Overactive Bladder Treatment Revenue (2017-2018)
    2.6.4 Main Business/Business Overview
    2.7 Hisamitsu Pharmaceutical Co., Inc.
    2.7.1 Company Basic Information and Its Competitors
    2.7.2 Hisamitsu Pharmaceutical Co., Inc. Product Category
    2.7.2.1 NEOXY Tape
    2.7.2.2 OABLOK PATCH
    2.7.3 Hisamitsu Pharmaceutical Co., Inc. Overactive Bladder Treatment Revenue (2017-2018)
    2.7.4 Hisamitsu Pharmaceutical Co., Inc. Recent Developments
    2.7.5 Main Business/Business Overview
    2.8 Sanofi
    2.8.1 Company Basic Information and Its Competitors
    2.8.2 Sanofi Product Category
    2.8.2.1 Ditropan
    2.8.3 Sanofi Overactive Bladder Treatment Revenue (2017-2018)
    2.8.4 Main Business/Business Overview
    2.9 Aurobindo Pharma Limited
    2.9.1 Company Basic Information and Its Competitors
    2.9.2 Aurobindo Pharma Limited Product Category
    2.9.2.1 solifenacin succinate
    2.9.3 Aurobindo Pharma Limited Overactive Bladder Treatment Revenue (2017-2018)
    2.9.4 Main Business/Business Overview
    2.1 Janssen Pharmaceuticals Inc
    2.10.1 Company Basic Information and Its Competitors
    2.10.2 Janssen Pharmaceuticals Inc Product Category
    2.10.2.1 DITROPAN XL
    2.10.3 Janssen Pharmaceuticals Inc Overactive Bladder Treatment Revenue (2017-2018)
    2.10.4 Main Business/Business Overview

    3 Global Overactive Bladder Treatment Market Competition, by Players
    3.1 Global Overactive Bladder Treatment Market Revenue and Share by Players (2017-2018)
    3.2 Market Concentration Rate
    3.2.1 Top 3 Overactive Bladder Treatment Players Market Share
    3.2.2 Top 5 Overactive Bladder Treatment Players Market Share

    4 Global Overactive Bladder Treatment Market Size by Regions
    4.1 Global Overactive Bladder Treatment Market Revenue, and Market Share by Regions
    4.2 North America Overactive Bladder Treatment Market Revenue, and Growth Rate (2014-2019)
    4.3 Europe Overactive Bladder Treatment Market Revenue, and Growth Rate (2014-2019)
    4.4 Asia-Pacific Overactive Bladder Treatment Market Revenue, and Growth Rate (2014-2019)
    4.5 South America Overactive Bladder Treatment Market Revenue, and Growth Rate (2014-2019)
    4.6 the Middle East & Africa Overactive Bladder Treatment Market Revenue, and Growth Rate (2014-2019)

    5 North America Overactive Bladder Treatment Market Revenue by Countries
    5.1 North America Overactive Bladder Treatment Market Revenue, By Countries (2014-2019)
    5.2 USA Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    5.3 Canada Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    5.4 Mexico Overactive Bladder Treatment Revenue and Growth Rate (2014-2019)

    6 Europe Overactive Bladder Treatment Market Revenue by Countries
    6.1 Europe Overactive Bladder Treatment Market Revenue, By Countries (2014-2019)
    6.2 Germany Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    6.3 France Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    6.4 UK Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    6.5 Italy Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    6.6 Russia Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Overactive Bladder Treatment Revenue by Countries
    7.1 Asia-Pacific Overactive Bladder Treatment Market Revenue, By Countries (2014-2019)
    7.2 China Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    7.3 Japan Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    7.4 Korea Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    7.5 India Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)

    8 South America Overactive Bladder Treatment Revenue by Countries
    8.1 South America Overactive Bladder Treatment Market Revenue, By Countries (2014-2019)
    8.2 Brazil Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    8.3 Argentina Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)

    9 The Middle East & Africa Revenue Overactive Bladder Treatment by Countries
    9.1 The Middle East & Africa Overactive Bladder Treatment Market Revenue by Countries (2014-2019)
    9.2 Saudi Arabia Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    9.3 UAE Overactive Bladder Treatment Revenue and Growth Rate (2014-2019)
    9.4 Egypt Overactive Bladder Treatment Market Revenue and Growth Rate (2014-2019)
    9.5 South Africa Overactive Bladder Treatment Revenue and Growth Rate (2014-2019)

    10 Global Overactive Bladder Treatment Market Segment by Type
    10.1 Global Overactive Bladder Treatment Market Revenue and Market Share by Type (2014-2019)
    10.2 Global Overactive Bladder Treatment Market Forecast by Type (2019-2026)
    10.3 Anticholinergics, Overactive Bladder Treatment Market Revenue (2014-2026)
    10.4 Mirabegron, Overactive Bladder Treatment Market Revenue (2014-2026)
    10.5 Botox, Overactive Bladder Treatment Market Revenue (2014-2026)
    10.6 Others, Overactive Bladder Treatment Market Revenue (2014-2026)

    11 Global Overactive Bladder Treatment Market Segment by Application
    11.1 Global Overactive Bladder Treatment Market Share by Application (2014-2019)
    11.2 Overactive Bladder Treatment Market Forecast by Application (2019-2026)
    11.3 Idiopathic Bladder Overactivity Revenue (2014-2026)
    11.4 Neurogenic Bladder Overactivity Revenue (2014-2026)

    12 Global Overactive Bladder Treatment Market Size Forecast (2019-2026)
    12.1 Global Overactive Bladder Treatment Market Size Forecast (2019-2026)
    12.2 Global Overactive Bladder Treatment Market Revenue Forecast by Regions (2019-2026)
    12.3 North America Overactive Bladder Treatment Revenue Market Forecast (2019-2026)
    12.4 Europe Overactive Bladder Treatment Revenue Market Forecast (2019-2026)
    12.5 Asia-Pacific Overactive Bladder Treatment Revenue Market Forecast (2019-2026)
    12.6 South America Overactive Bladder Treatment Revenue Market Forecast (2019-2026)
    12.7 The Middle East & Africa Overactive Bladder Treatment Revenue Market Forecast (2019-2026)

    13 Appendix
    13.1 Methodology
    13.2 Primary Research
    13.3 Research Methodology
    13.4 Assumptions & Exclusions
    13.5 Secondary data sources
    13.6 Disclaimer

    keyboard_arrow_up
    • The following manufacturers are covered:
      • Astellas Pharma, Inc.
      • Pfizer, Inc.
      • Teva Pharmaceutical Industries Limited
      • Allergan, PLC
      • Mylan N.V
      • Endo International PLC
      • Hisamitsu Pharmaceutical Co., Inc.
      • Sanofi
      • Aurobindo Pharma Limited
      • Johnson & Johnson
    keyboard_arrow_up


    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CLIENTS